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Abstract
BACKGROUND & AIMS—It is not clear whether evidence-based recommendations for 
inpatient care of patients with cirrhosis are implemented widely or are effective in the community. 
We investigated changes in inpatient outcomes and associated features over time.
METHODS—By using the Healthcare Cost and Utilization Project, National Inpatient Sample, 
we analyzed 781,515 hospitalizations of patients with cirrhosis from 2002 through 2010. We 
compared data with those from equal numbers of hospitalizations of patients without cirrhosis and 
patients with congestive heart failure (CHF), matched for age, sex, and year of discharge. The 
primary outcome was a change in discharge status over time. Factors associated with outcomes 
were analyzed by Poisson modeling.
RESULTS—The mortality of patients with and without cirrhosis, and patients with CHF, 
decreased over time. The absolute decrease was significantly greater for patients with cirrhosis 
(from 9.1% to 5.4%) than for patients without cirrhosis (from 2.6% to 2.1%) or patients with CHF 
(from 2.5% to 1.4%) (P < .01). However, relative decreases were similar for patients with 
cirrhosis (41%) and patients with CHF (44%). For patients with cirrhosis, the independent 
mortality risk ratio decreased steadily to 0.50 by 2010 (95% confidence interval, 0.48–0.52), 
despite patients’ increasing age and comorbidities. Hepatorenal syndrome, hepatocellular 
carcinoma, variceal bleeding, and spontaneous bacterial peritonitis were associated with a higher 
mortality rate, but the independent mortality risks for each decreased steadily. Sepsis was 
associated strongly with increased mortality, and the risk increased over time.
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CONCLUSIONS—Among patients with cirrhosis in the United States, inpatient mortality 
decreased steadily from 2002 through 2010, despite increases in patient age and medical 
complexity. Improvements in cirrhosis care may have contributed to increases in patient survival 
beyond those attributable to general improvements in inpatient care. Further improvements might 
require an increased use of proven therapies and the development of new treatments—particularly 
for sepsis.
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Cirrhosis is the eighth leading cause of death and years of life lost in the United States.1 The 
course of cirrhotic liver failure often requires hospitalizations for complications such as 
renal failure, variceal bleeding, ascites, hepatic encephalopathy, and hepatocellular 
carcinoma. In addition, cirrhosis affects the outcome of non–liver-related illnesses requiring 
hospitalization. Care of cirrhosis patients is complex and often is managed by a team of 
specialists including gastroenterologists, hepatologists, intensivists, and nephrologists. The 
risk of mortality can be high, but careful management can mitigate this risk.2–5 Over the past 
10 to 15 years, significant advancements have been made in the management of hepatorenal 
syndrome (HRS), variceal bleeding, spontaneous bacterial peritonitis (SBP), ascites, and 
hepatocellular carcinoma (HCC).6–9 Such advances have led to the dissemination of several 
evidence-based practice guidelines by all 3 major hepatology associations.10–12 Cirrhotic 
patients also may benefit from non–liver-specific guidelines such as sepsis care, particularly 
early identification of the systemic inflammatory response syndrome, and antibiotic 
administration.13
Studies have indicated that guideline dissemination and implementation are effective in 
changing practice behaviors and improving patient outcomes.14,15 Therefore, we 
hypothesized that guidelines for inpatient cirrhosis care have penetrated the wider medical 
community and have resulted in better outcomes. We analyzed a large, nationally 
representative sample of cirrhosis patients who were hospitalized from 2002 through 2010 
across the United States. Our goal was to see if inpatient mortality of cirrhotic patients has 
improved over time and to evaluate clinical variables associated with mortality including 
specific cirrhosis-related diagnoses and interventions.
Materials and Methods
Data Source
Data were extracted from discharges in the Nationwide Inpatient Sample (NIS), Healthcare 
Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality for the 
years 2002–2010.16 The HCUP NIS is a 20% stratified sample of hospitals in the United 
States. It is the largest all-payer inpatient care database with hospitals spread across 46 
states, and these states comprise more than 97% of the US population. The HCUP NIS 
contains more than 8 million hospital stays per year from more than 1000 hospitals. A full 
range of hospitals is sampled including community and academic centers. Data are entered 
as individual discharge records. Each record has a unique identifier, demographic data, 
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hospital type, admission type, transfer status, hospitalized inpatient mortality indicator, 
discharge to palliative care, primary diagnosis, secondary diagnoses (up to 15), and 
procedure codes (up to 15). Admission diagnoses are not included in this data set. Time 
from admission to various primary procedures (eg, endoscopy and paracentesis) is provided 
as well as a diagnosis and procedure groups and patient comorbidity elements. Third-party 
payer status is included in the data set, however, “self-pay” is not defined further (ie, paid 
out of pocket vs inability to pay).
Cohort selection—The HCUP NIS contains 71,718,458 individual discharge records 
from 2002 through 2010. By using the International Classification of Diseases, 9th revision, 
Clinical Modification (ICD-9-CM) diagnostic and procedural codes, we extracted the 
subpopulation of patient admissions with cirrhosis (n = 781,678) from the HCUP NIS 
database (Supplementary Table 1). We included hospital discharges from 2002 through 
2010 that had one or more of the following diagnoses: alcoholic cirrhosis of liver (571.2), 
biliary cirrhosis (571.6), or cirrhosis without mention of alcohol (571.5). Identification of 
cirrhotic patients using these codes in administrative data from the Veterans Affairs had a 
positive predictive value of 90% and a negative predictive value of 87%.17 We included 
elective admissions (n = 57,960).
To determine whether changes in mortality were specific to cirrhosis care, we compared 
mortality data between the cirrhotic cohort and a noncirrhotic (NC) cohort matched 1:1 on 
age, sex, and year of discharge. Inpatient care of congestive heart failure also has advanced. 
Therefore, we compared mortality data between the cirrhotic cohort and a noncirrhotic 
cohort with congestive heart failure (CHF), matched 1:1 on age, sex, and year of discharge. 
After matching, each cohort contained 781,515 hospitalizations. These cohorts became the 
focus of our analyses.
Outcomes, primary variables, and covariates—Our primary outcome was “died 
while hospitalized,” as labeled in the HCUP NIS. The secondary outcome was discharge to 
palliative care. Our primary independent variable was year of discharge. Primary covariates 
of interest were 5 cirrhosis-related diagnoses, which can be fatal and require specific 
interventions: HRS, HCC, variceal bleeding, sepsis, and SBP. We also examined 3 
procedures: esophagogastroduodenoscopy (EGD) within 1 day of admission, paracentesis 
within 1 day of admission, and transvenous intrahepatic portosystemic shunt (TIPS) at any 
time during the stay. These are captured readily in the HCUP NIS. Unfortunately, many 
other important cirrhosis-related interventions and diagnostic tests (eg, albumin use for SBP) 
are not captured and therefore were not available for analysis. Twenty-eight of the Agency 
for Healthcare Research and Quality comorbidity measures contained in the HCUP NIS 
were combined to generate the Elixhauser Comorbidity Index.18,19 Use of this index to 
adjust for comorbidities in administrative databases was supported by Austin et al19 using 
mathematic proofs. Major diagnoses and predictive covariates were defined using ICD-9-
CM codes and are shown in Supplementary Table 1. To define the time to paracentesis or 
EGD, the HCUP NIS data element indicating the day on which the procedure was performed 
was used in conjunction with the primary procedure. If EGD or paracentesis was performed 
within 1 day after admission, we captured it using a combination of a time-to-procedure 
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code and our primary diagnosis codes.16 We also adjusted for a length of stay less than 2 
days because many of these hospitalizations may represent the extremes of mortality risk 
that are less influenced by inpatient care (eg, moribund status, false alarm admissions for 
spurious laboratory results, and overnight observations after minor procedures). Patient 
demographic (eg, age, sex) and hospital characteristics (eg, academic, community based) 
were extracted from the HCUP NIS and included in the analysis.
Statistical analyses—Data were analyzed using the Stata 12.0 software package (Stata 
Corp LP, College Station, TX). HCUP NIS data are provided in a 2-stage cluster design 
incorporating clustering at the hospital level and discharge level. HCUP provides weighting 
of discharges based on the hospital type and volume of discharges relative to their sampling 
region. Two-way chi-square analyses were performed on categoric variables and t tests were 
performed for continuous variables. Poisson regression with robust (Huber–White) standard 
errors was used to determine incident risk ratios (RR) for predictors of in-hospital 
mortality.20 We tested the Poisson models for overdispersion using a Pearson goodness-of-
fit test. Models were not overdispersed (P = 1.00) and were appropriate for our analyses. 
Regression analyses controlled for several variables including calendar year of admission, 
major diagnostic and procedures covariates, age, sex, race, primary payer, Elixhauser 
comorbidity index, admission source, length of stay, and weekend admission. Referent 
categories were admission year 2002, age younger than 40 years, male sex, white, a routine 
admission, and self-pay listed as the primary payer.
We also hypothesized that an increased uptake of specific guidelines for the care of HRS, 
SBP, sepsis, variceal bleed, and HCC may have improved survival and would be reflected in 
decreasing mortality risk ratios from year to year. Therefore, we created interaction terms 
between each diagnosis and year of discharge (eg, HRS × 2002, HRS × 2003, and so forth). 
A more appropriate use of EGD within 1 day of admission, paracentesis within 1 day of 
admission, and TIPS may have led to similar decreasing risk ratios for inpatient mortality 
over time. To investigate this possibility, we created interaction terms between each of these 
interventions and year of discharge (eg, TIPS × 2002, TIPS × 2003, and so forth). We also 
examined EGD within a day, paracentesis within a day, and TIPS at any time during the 
hospitalization restricted to patients with a variceal bleed or ascites.
Study Approval and Data Use Agreement
The Institutional Review Board of the University of North Carolina at Chapel Hill approved 
the research protocol before beginning this research. A data use agreement was in place with 
the Agency for Healthcare Research and Quality for use of the HCUP NIS data.
Results
Patients Characteristics and Univariate Analyses of In-Hospital Mortality
Patient demographics for all 781,515 hospitalizations of patients with cirrhosis are presented 
in Table 1, along with the subgroups of hospitalizations ending in discharge without hospice 
care (713,537 [91.3%]), death in the hospital (57,955 [7.4%]), and discharge to hospice care 
(10,023 [1.3%]). Although the number of cirrhosis hospitalizations increased over the years, 
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the proportion of patients dying in the hospital decreased (Table 1). Alcohol-related liver 
disease was present in nearly half of all admissions, and ascites and encephalopathy were the 
most common cirrhosis-related complications. More than two thirds were admitted through 
the Emergency Department (ED) and slightly less than two thirds had Medicaid and/or 
Medicare coverage. Although 33% had a diagnosis of ascites, only 9.2% had paracentesis on 
the first day of hospitalization.
Patients who died had a higher proportion of cirrhosis complications, especially HRS and 
sepsis. A higher proportion of patients who died were transferred from another hospital or 
were hospitalized for a short time (<2 days). Patients discharged to hospice had a 
significantly higher prevalence of HCC, but a lower proportion of transfers from another 
hospital. Both increased age and comorbidities were more common in patients who died or 
were discharged to hospice, but skewing toward increased age and amount of comorbidities 
was even higher in the hospice subgroup (30.2% older than age 70 and mean Elixhauser 
Comorbidity Index of 3.3). Several variables such as payer status, race, sex, and admission 
on a weekend were statistically different, but the differences were of unclear clinical 
significance.
Trends Over Time
Despite an increase in hospitalizations involving cirrhosis, inpatient mortality rates steadily 
decreased from 9.1% in 2002 to 5.4% in 2010. The mortality rates for the noncirrhotic and 
the noncirrhotic, CHF cohorts decreased, but to a significantly lesser degree (Figure 1). 
However, the relative decrease in mortality was similar for cirrhosis and CHF patients (41% 
and 44% decreases, respectively), and was smallest for the noncirrhotic cohort (19% 
decrease). The improvement in survival for cirrhosis patients occurred despite increasing 
age and comorbidities. There was steady increased skewing toward increased age brackets 
over time (70.5% in age >50 y in 2002, vs 77.9% in age >50 in 2010). The mean Elixhauser 
Comorbidity Index for cirrhosis patients was 2.5 in 2002 and steadily increased to 3.4 by 
2010 (P < .05). Nevertheless, inpatient mortality rates for cirrhosis patients decreased across 
all age brackets, even those older than ages 70 and 80 years (Figure 2). Length of stay also 
decreased steadily from a mean of 6.95 days in 2002 to 5.88 days in 2010 (P < .001). Our 
secondary outcome, discharged to palliative care, was used infrequently but increased 
steadily by 4-fold from 0.4% in 2002 to 1.7% in 2010 (P < .05).
Multivariate Analysis of In-Hospital Mortality and Discharge to Palliative Care
By Poisson regression, each passing year was associated independently with decreasing risk 
(RR) of inpatient mortality (P < .001) (Tables 2 and 3, Figure 3). By 2010, the risk of dying 
in the hospital had decreased by 50% (RR, 0.50; 95% confidence interval [CI], 0.48–0.52) 
compared with 2002. As expected, increased age, sepsis, HRS, variceal bleed, and HCC all 
were associated independently with increased risk of death. The highest independent risks 
for death were seen with sepsis (RR, 4.70; 95% CI, 4.61–4.79) and HRS (RR, 3.39; 95% CI, 
3.31–3.47). Starting the hospitalization as a transfer from another hospital increased the 
mortality risk by 60%. Having some form of insurance or third-party payer was associated 
with a lower mortality rate compared with self-pay. Hospital type (eg, academic vs 
community based) was not associated with mortality risk (data not shown). Controlling for 
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hospitalization for shorter than 1 day, instead of fewer than just 2 days, and excluding the 
1.3% of cirrhosis patients discharged to palliative care, did not significantly change any of 
the incident risk ratios shown in Table 2. The noncirrhotic cohort with CHF had a similar 
50% decrease in their mortality risk ratio, whereas the overall noncirrhotic comparison 
cohort had a 34% decrease in risk (Table 2).
The mortality risk ratios for the interaction terms of cirrhosis-related diagnoses (HRS, SBP, 
variceal bleed, and HCC) by discharge year all decreased (Figure 3 and Supplementary 
Table 1), with the most remarkable decrease occurring for HRS. Thus, for each cirrhosis 
complication, except sepsis, the risk of dying was lower in 2010 compared with 2002. In 
contrast, the risk of dying for a cirrhosis patient with sepsis was 28% higher (RR, 3.62; 95% 
CI, 3.32–3.95 in 2002; vs RR, 4.63; 95% CI, 4.41–4.86 in 2010). The mortality risk for EGD 
within 1 day of admission, paracentesis within 1 day of admission, and TIPS also tended to 
decrease over time.
To further examine the effect of early EGD, early paracentesis, and TIPS, we reran the 
Poisson model restricting patients to those with variceal bleed or ascites. When we restricted 
the model to patients with ascites, paracentesis within 1 day of admission was associated 
independently with a 12% decrease in mortality risk (RR, 0.88; 95% CI, 0.84–0.92). 
However, when we restricted the model to patients with a variceal bleed, EGD within 1 day 
of admission was associated with a 22% increased risk of death (RR, 1.22; 95% CI, 1.15–
1.30). TIPS at any time during the hospitalization had a mortality RR of 1.17 (95% CI, 1.08–
1.27) when restricted to patients with ascites, and 1.94 (95% CI, 1.79–2.11) when restricted 
to patients with variceal bleeding.
Multivariate Poisson modeling for our secondary outcome of discharge to palliative care 
(Table 3) showed similar associations compared with our primary outcome of mortality 
(Table 2), but there were notable differences. Risk ratios for discharge to palliative care 
increased from year-to-year, consistent with its increase in use. Although increasing age, 
HRS, and HCC all were associated independently with palliative care discharges, the 
association was smaller for HRS and larger for HCC when compared with their risks of 
mortality. Interestingly, sepsis, TIPS, length of stay fewer than 2 days, admission through 
the ED, and transfer from an outside facility carried lower risk ratios of being discharged to 
palliative care.
Discussion
In this large representative sample of US hospitalized patients with cirrhosis, we found 
reduced inpatient mortality rates from 2002 through 2010. The absolute rate of dying in the 
hospital decreased steadily by 41% from 9.1% in 2002 to 5.4% in 2010 (Figure 1). On 
multivariate analysis, the incident RR of mortality also decreased steadily by 50% (RR, 
0.50; 95% CI, 0.48–0.53 by 2010) (Table 2). The decrease in mortality rate for cirrhosis 
patients was significantly larger compared with NC patients (Figure 1 and Table 2). NC 
patients had only a 0.5% absolute decrease in mortality, representing a 19% relative 
decrease and a 34% decrease in risk of death on multivariate analysis (RR, 0.66). Therefore, 
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the improvement in cirrhosis survival may be owing to better cirrhosis-specific care that 
extends beyond general improvements in inpatient care.
This consistent decrease in mortality rate and risk for cirrhosis patients, year to year, 
occurred despite increasing age and comorbidities. Indeed, the inpatient mortality rate 
decreased across all age groups (Figure 2). The steady decrease in mortality risk was 
independent of several cirrhosis-related diagnoses, payer status, sex, and race (Table 2), and 
persisted after excluding patients discharged to palliative care and patients hospitalized for 
only 1 or 2 days. Noncirrhotic CHF patients had a smaller absolute decrease in mortality rate 
from 2.5% to 1.4%, but the relative decrease and change in mortality risk (40% and 50% 
decreases, respectively) were similar to patients with cirrhosis. Improving CHF care and 
outcomes have been suggested in other studies.21,22
A single-center study from the United States and a regional study from Spain also suggested 
improved survival for cirrhosis patients over time, but these studies had smaller cohorts, did 
not control for palliative care discharges, and did not compare outcomes with noncirrhotic or 
non–liver-related chronic disease cohorts.23,24 Our study, using the HCUP NIS, included a 
large cohort and spanned a nation. The HCUP NIS is a 20% sampling of US hospitals, 
stratified by several variables including region and hospital type. Strong associations 
between inpatient mortality and well-known risk factors such as increased age, sepsis, and 
HRS lend validity to our data and modeling (Table 2). Therefore, our findings of decreasing 
inpatient mortality and risk of death are well supported and representative of inpatient 
cirrhosis care across the United States.
Improvement in cirrhosis care may be contributing to this decrease in inpatient mortality 
rates. Several guidelines and reviews regarding the management of HRS, SBP, variceal 
bleed, and HCC have been published in the past 10–15 years.6,9,10,25–29 Interaction terms 
between these complications and year of discharge yielded a decrease in mortality RRs for 
each diagnosis. HRS and SBP had the largest percentage decreases in mortality risk (HRS: 
RR, 5.6, 95% CI [5.6–6.0] to 3.2 [3.0–3.4]; SBP: RR, 1.9 [1.7–2.1] to 1.2 [1.1–1.3]), 
suggesting that patients admitted with either HRS or SBP had a roughly 40% better chance 
of survival in 2010 compared with 2002 (Figure 3, Supplementary Table 2). Over the past 
10–15 years, the diagnosis and management of HRS has been clarified by the International 
Ascites Club, which may have led to earlier diagnoses and more use of albumin and 
vasoactive medications.30 Similarly, clear recommendations for early diagnostic 
paracentesis and use of albumin for SBP may be penetrating community practice.9,10
However, we were unable to link improved outcomes with the few cirrhosis-specific 
interventions available in this data set. As seen in a prior study using the HCUP NIS,31 
paracentesis within 1 day of admission for patients with ascites was associated with a 12% 
mortality risk reduction among cirrhotic patients with ascites, but we did not see an 
increased use of early paracentesis over time. EGD within 1 day was associated with an 
increase in mortality among those with variceal bleeding, which runs counter to guidelines 
for early endoscopy. Early EGD probably is performed more commonly with severe and 
rapidly bleeding patients which creates a selection bias for patients with a higher mortality 
risk. Similarly, TIPS at any time during the hospitalization was associated with a higher 
Schmidt et al. Page 7













mortality rate probably because it is used for more advanced portal hypertension. When 
restricted to variceal bleed patients, there was an even higher mortality risk, which reflects 
the increased acuity for patients failing endoscopic control of bleeding. Unfortunately, the 
HCUP NIS does not contain details on the many other cirrhosis care interventions that have 
evolved in the past 10–15 years. Uptake of these other evidence-based recommendations 
could explain the decreases in mortality risk. Indeed, it is difficult to explain such consistent 
decreases without some attribution to improvement in cirrhosis care.
The independent mortality risk for sepsis increased over time to surpass the risk related to 
HRS (Figure 3). It occurred despite the ongoing “surviving sepsis campaign.” The reasons 
for this increase are unclear and are at odds with a recent study that also used the HCUP 
NIS, which suggests that overall sepsis mortality rates are decreasing. However, hepatic 
“end-organ failure” made up only 4%-5% of all sepsis patients and no cirrhosis-specific 
analyses were provided. Cirrhosis patients have particularly poor hemodynamic reserve, 
with wider perturbations in immune inflammatory and compensatory responses that could 
hinder survival.34 Therefore, it is possible that cirrhosis patients are doing much worse with 
sepsis compared with other patients. The surviving sepsis campaign may need guidelines 
that specifically target cirrhosis patients.
Although the use of palliative care discharges remains low, its increase (0.4%–1.7%) is 
noteworthy. Patients discharged to palliative care tended not to be admitted by transfer from 
another hospital or through the ED (Table 3). Palliative care was associated strongly with 
increased age, hepatic decompensation, HCC, and comorbidities. Thus, the increase in 
palliative care probably represents an improvement in care. Unnecessary morbidity can be 
significant for advanced liver failure patients if palliative care is not implemented. In a 
Canadian study, where only 11% of cirrhotic patients deemed inappropriate for transplant 
received palliative care, 80% went on to be hospitalized, 50% received intensive care unit 
care, and 53% died as inpatients.35 The investigators and the authors of an accompanying 
editorial argued that palliative care would have prevented suffering, and is woefully 
underutilized.36 We confirm low use in the United States, but also a 4-fold increase since 
2002.
The HCUP NIS is limited by its inability to identify individual patients who are re-admitted. 
Therefore, the decrease in mortality rates for cirrhotic patients could be owing partly to 
increased re-admissions. If discharges are premature or poorly executed, leading to 
unnecessary readmissions or death at home, then any claim of improved quality of care is 
undermined. Indeed, the length of stay decreased from a mean of 6.95 days in 2002 to 5.88 
days in 2010 (P < .001). However, better inpatient care also leads to a shortened length of 
stay and increased re-admissions. Need for hospitalization increases as part of the dying 
process for many cirrhotic patients, particularly if hospitals become better at saving sicker 
cirrhotic patients year after year. Indeed, re-admission rates have been criticized as a poor 
quality indicator for just this reason.37 Overall, as few as 12% of re-admissions may be 
preventable, and lower inpatient mortality rates for heart failure patients has been associated 
with re-admissions because the sickest patients are kept alive only to be re-admitted.38,39 A 
similar relationship between better inpatient care and increased re-admissions would be 
particularly true for an aging cirrhotic population with increasing comorbidities. A single-
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center retrospective study showed a 37%, 30-day re-admission rate for cirrhosis patients, 
and 78% were deemed unavoidable.40
As with any administrative data set, the accuracy and scope of data had limitations. ICD-9-
CM codes can be inaccurate, particularly for liver-related codes other than cirrhosis.41 
However, our use of several combined liver-related diagnostic codes has been shown to 
have greater accuracy31,41–43 (Supplementary Table 1). We used several cirrhosis codes that 
have high positive (90%) and negative (87%) predictive values.17 Misclassification of 
discharge diagnoses was quite low in this data set. The 2011 HCUP NIS Data Quality 
Report indicated that only 0.06% of the discharge summaries checked against the American 
Hospital Association database were missing principle diagnoses, and only 0.06% had invalid 
diagnoses. The HCUP NIS does not capture many liver failure severity variables and 
laboratory results accurately (eg, model for end-stage liver disease and Child–Pugh scores). 
Although there is no reason to believe the severity of liver failure among hospitalized 
patients decreased over the years, we could not test for such an influence on improving 
survival. Finally, we cannot comment on longer-term (eg, 3 and 6 months), post-discharge 
outcomes with this data set.
Nonetheless, our study represents outcomes of a large sampling of hospitalized cirrhotic 
patients and spans a nation over nearly a decade. The improving inpatient survival despite 
aging and more medically complex cirrhotic patients is remarkably consistent across several 
cirrhosis complications and suggests improving cirrhosis care that may extend beyond 
general improvements in inpatient care. On the other hand, sepsis had an increasing 
mortality risk, suggesting that cirrhotic patients may need a more tailored approach to sepsis. 
Use of palliative care will continue to increase and likely reflects an appropriate transition 
for older and medically complex cirrhotic patients. As cirrhosis-related admissions continue 
to increase and hospitals increasingly are held accountable for outcomes, our data may help 
in setting appropriate quality care indicators, including guideline use, adjusted mortality 
risk, and use of palliative care.
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HCUP NIS Healthcare Cost and Utilization Project, National Inpatient Sample
HRS hepatorenal syndrome
ICD-9-CM International Classification of Diseases, 9th revision, Clinical Modification
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SBP spontaneous bacterial peritonitis
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Inpatient mortality from 2002 to 2010 for cirrhotic patients, NC patients, and NC patients 
with CHF. NC and NC-CHF patients were matched 1:1 with cirrhotic patients on age, sex, 
and year of discharge. The decrease in mortality for patients with cirrhosis was significantly 
more than that in the NC and NC-CHF cohorts.
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Inpatient mortality from 2002 to 2010 for cirrhotic patients by age group.
Schmidt et al. Page 14














Incident risk ratios for cirrhosis complications or interventions, each year from 2002 to 
2010. Derived from interaction terms (eg, HRS × 2002, × 2003, to × 2010; sepsis × 2002, × 
2003, to 2010) in Poisson model for inpatient mortality. (Para = paracentesis).
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Table 3
Poisson Incident Risk Ratios for Discharge to Hospice Among Cirrhotic Patients
Variable Risk ratioa (95% CI) P value
Year of discharge
    2002 Referent
    2003 1.94 (1.68–2.25) <.001
    2004 2.85 (2.49–3.27) <.001
    2005 3.49 (3.06–3.99) <.001
    2006 3.60 (3.16–4.11) <.001
    2007 3.46 (3.03–3.94) <.001
    2008 3.37 (2.95–3.85) <.001
    2009 3.49 (3.07–3.98) <.001
    2010 3.60 (3.16–4.10) <.001
Sex
    Male Referent
    Female 0.94 (0.90–0.98) .002
Age, y
    <40 Referent
    41–50 1.11 (0.98–1.24) .096
    51–60 1.44 (1.28–1.61) <.001
    61–70 1.83 (1.63–2.05) <.001
    71–80 2.64 (2.33–2.98) <.001
    >80 3.50 (3.07–3.98) <.001
Race/ethnicity
    White Referent
    Black 0.90 (0.87–0.97) .007
    Hispanic 0.71 (0.67–0.76) <.001
Diagnoses
    HRS 2.28 (2.12–2.44) <.001
    HCC 3.49 (3.30–3.69) <.001
    Variceal hemorrhage 1.15 (1.06–1.24) .001
    SBP 1.07 (0.97–1.18) .156
    Ascites 1.18 (1.12–1.23) <.001
    Encephalopathy 1.73 (1.66–1.81) <.001
    Sepsis 0.91 (0.83–0.99) .024
Comorbidities
    Elixhauser Comorbidity Index 1.05 (1.04–1.06) <.001
Procedures
    EGD 0.63 (0.58–0.68) <.001
    EGD <1 day from admission 0.97 (0.87–1.09) .649
    Paracentesis 1.91 (1.80–2.02) <.001
    Paracentesis <1 day from admission 0.95 (0.89–1.02) .167
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Variable Risk ratioa (95% CI) P value
    Thoracentesis 1.41 (1.24–1.60) <.001
    Thoracentesis <1 day from admission 0.96 (0.78–1.17) .655
    TIPS 0.56 (0.45–0.71) <.001
Length of stay
    <2 days 0.63 (0.8–0.68) <.001
Admission source/day
    Routine admission Referent
    Admitted on weekend 1.06 (1.01–1.11) .013
    ED admission 0.78 (0.75–0.82) <.001
    Outside hospital admission 0.71 (0.62–0.80) <.001
    Court/law admission 0.14 (0.03–0.54) .005
Primary payor
    Self-pay Referent
    Private insurance 0.74 (0.68–0.80) <.001
    Medicaid 0.80 (0.73–0.87) <.001
    Medicare 0.77 (0.71–0.84) <.001
    Other payment method 1.29 (1.16–1.44) <.001
a
Using robust standard errors and adjusted for length of stay.
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